Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Sjögren-Larsson syndrome (SLS) is a rare autosomal recessive neurocutaneous disorder characterized by congenital ichthyosis, spastic diplegia or paraplegia, and intellectual disability, caused by deficient activity of fatty aldehyde dehydrogenase (FALDH) encoded by ALDH3A2 (PMID:20142464).
Multiple case reports describe biallelic ALDH3A2 variants in affected siblings and extended families: a homozygous nonsense variant c.1320T>A (p.Tyr440Ter) in five consanguineous relatives (PMID:32930514), compound heterozygous c.1291_1292del (p.Lys431fs) and c.798+1del in adolescent-onset neurodegeneration (PMID:30157790).
In an MRI/MRS cohort of 11 FALDH-deficient patients, all exhibited the characteristic ichthyosis and retinal glistening dots, while variable dysmyelination and lipid accumulation correlated with neurologic severity (PMID:10227616).
A mutation screen of 63 kindreds identified 49 unique ALDH3A2 defects, including 22 missense, 10 deletions, 3 nonsense, 9 splice-site, and 3 complex alleles; recurrent founder mutation C943T (p.Pro315Ser) accounts for ~24% of alleles in Northern European families (PMID:10577908, PMID:9204959).
Functional assays demonstrate that missense and nonsense substitutions abolish FALDH catalytic activity, splice-site variants lead to aberrant transcripts, and alternative splicing yields peroxisomal versus ER isoforms, confirming loss-of-function as the pathogenic mechanism (PMID:9204959, PMID:17510064).
Collectively, these data provide definitive evidence that biallelic ALDH3A2 mutations cause Sjögren-Larsson syndrome with consistent genotype–phenotype correlations. Key take-home: targeted sequencing of ALDH3A2 in patients with ichthyosis, spastic diplegia, and intellectual disability enables accurate diagnosis, genetic counseling, and early intervention.
Gene–Disease AssociationDefinitiveBiallelic ALDH3A2 variants in >150 patients across >90 families with consistent segregation and functional concordance Genetic EvidenceStrongBi-allelic ALDH3A2 mutations in >100 patients from consanguineous and unrelated families reaching the ClinGen cap Functional EvidenceStrongMultiple in vitro and cell-based studies demonstrate abolished FALDH activity and isoform-specific defects |